Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Afatinib + paclitaxel
- Development stage
- Phase 3
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Afatinib + paclitaxel is a combination therapy used in oncology, particularly for patients with advanced solid tumors and metastatic breast cancer who have failed prior HER2-targeted therapies. Afatinib is an irreversible inhibitor of the ErbB family of tyrosine kinases, including EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4). It blocks intracellular signaling pathways involved in tumor cell proliferation and survival. Paclitaxel is a microtubule-stabilizing agent that inhibits cell division by promoting tubulin polymerization and preventing microtubule disassembly. The combination has demonstrated objective responses in clinical trials, with manageable toxicity profiles. This regimen has been studied for use in metastatic breast cancer, non-small cell lung cancer, and other advanced solid tumors[1][2][3][6][8].
- Brand names
- Abraxane
- Other names
- BIBW2992BIBW-2992BIBW 2992afatinib dimaleate
02
Targets
ABCB1 (P-glycoprotein)EGFR (Epidermal growth factor receptor)ERBB4 (Erb-b2 receptor tyrosine kinase 4)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Afatinib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Afatinib + paclitaxel.